Drivers of de novo Serine/Glycine synthesis in acute leukemia

Paulien Verstraete; Kim De Keersmaecker; Kim Rosalie Kampen

doi:10.1002/1873-3468.14700

Drivers of de novo Serine/Glycine synthesis in acute leukemia

FEBS Lett. 2023 Sep;597(17):2145-2146. doi: 10.1002/1873-3468.14700. Epub 2023 Aug 1.

Authors

Paulien Verstraete^{1

2}, Kim De Keersmaecker^{1

2}, Kim Rosalie Kampen^{1

2

3}

Affiliations

¹ Laboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven, Leuven, Belgium.
² Leuven Cancer Institute (LKI), Leuven, Belgium.
³ Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht, The Netherlands.

PMID: 37526379
DOI: 10.1002/1873-3468.14700

Abstract

Cancer cells hijack metabolic pathways in order to provide themselves with building blocks to support their proliferation and survival. Upregulation and addiction to de novo serine/glycine synthesis is an example of metabolic rewiring in cancer cells whereby serine and glycine are synthesised via a side branch of glycolysis. In this review, we focus on upregulation of endogenous serine/glycine production in acute leukemia, namely T-cell acute leukemia (T-ALL) and acute myeloid leukemia (AML). Several genetic lesions directly driving the serine/glycine addiction in acute leukemia have been established. Additionally, indirect regulation of de novo serine/glycine synthesis is observed in acute leukemia.

Keywords: ALL; AML; DNMT3A; FLT3-ITD; NKX2-1; NOTCH1; RPL10; glycine; serine; sertraline.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Myeloid, Acute* / metabolism
Mutation
Transcriptional Activation
Up-Regulation